Abstract: IgG epitope and applications thereof as a target are provided. The IgG epitope is the CH1 domain of non-B cell-derived IgG, and there is N-glycosylated sialic acid modification at the Asn162 site of the domain. The realization of its antigen functions must depend on the sialylation of the site. The present invention further discloses the applications of the IgG epitope as a drug target in preparing drugs for diagnosis and/or treatment of epithelial tumors. In addition, our studies showed that this antigen depends on the sialylation of Asn162 site as a drug target, and the sialylation of this site must depend on sialyltransferase ST3GAL4, indicating that the enzyme can be used as a drug target for preparing tumor therapeutic drugs. Further, integrin ?4 is co-expressed and co-localized with IgG containing the epitope. IgG can be used as a marker for preparing drugs for the auxiliary detection of epithelial tumors.

Abstract: The present invention relates to an anticancer drug, an energized fusion protein Anti-CD20(Fab)-LDM of lidamycin, a gene encoding the same; and further relates to a method for construction of the energized fusion protein in a genetic engineering manner and the use of the energized fusion protein. The applicant provides an anti-tumor drug with a good targeting ability by providing the energized fusion protein.